Skip to main content
Jonathan Brammer, MD, Hematology, Columbus, OH

JonathanEdwardBrammerMD

Hematology • Columbus, OH

Medical Resident, Medicine, Baylor College of Medicine

Join to view full profile

Dr. Brammer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Brammer's full profile

Already have an account?

  • Office

    460 W 10th Ave
    Columbus, OH 43210
    Phone+1 614-293-3196
    Fax+1 614-293-7526

Education & Training

  • Oregon Health & Science University (OHSU Health)
    Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2012 - 2015
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Internal Medicine, 2009 - 2012
  • Northeast Ohio Medical University
    Northeast Ohio Medical UniversityClass of 2009

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2012 - Present
  • OH State Medical License
    OH State Medical License 2016 - 2025
  • TX State Medical License
    TX State Medical License 2011 - 2019

Publications & Presentations

PubMed

Abstracts/Posters

  • Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...
    Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
    Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
    Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • New Three-Drug Combo Stimulates 'Master Cancer Killer' Cells, Boosts Immune System of Patients Undergoing Stem Cell Transplantation
    New Three-Drug Combo Stimulates 'Master Cancer Killer' Cells, Boosts Immune System of Patients Undergoing Stem Cell TransplantationJanuary 3rd, 2022
  • Duvelisib Tested in Rare Lymphoma Subtype
    Duvelisib Tested in Rare Lymphoma SubtypeMarch 4th, 2020
  • Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to Go
    Promising Cancer Treatment Which Made Patients Worse Shows How Far There Is to GoJune 7th, 2018
  • Join now to see all

Dr. Jonathan Brammer, Dr. Jonathan Brammer, MD, Dr. J Brammer, Dr. Jonathan Edward Brammer